Navidea Biopharmaceuticals Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	pas de données

Mises à jour récentes de la gestion

Recent updates

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Feb 10

PDG

Navidea Biopharmaceuticals n'a pas de PDG, ou nous n'avons pas de données sur eux.

Navidea Biopharmaceuticals Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Navidea Biopharmaceuticals, Inc. Announces Board Resignations

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023

Navidea Biopharmaceuticals, Inc. Announces Executive Changes

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Announces Board Changes

High number of new and inexperienced directors

Recent updates

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

Navidea Biopharmaceuticals, Inc. Announces Board Resignations

Navidea Biopharmaceuticals, Inc. Files Form 15

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023

Navidea Biopharmaceuticals Requests Oral Hearing with NYSE Hearing Panel

NYSE American Determines to Commence Proceedings to Delist the Common Stock of Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. Announces Executive Changes

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals Proposes Reverse Stock Split, Stock-For-Debt Swap to End Its Threat of De-Listing

New major risk - Shareholder dilution

High number of new and inexperienced directors

Navidea Biopharmaceuticals Receives NYSE American Notice

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Navidea Biopharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.56 loss per share (vs US$0.40 loss in FY 2021)

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc. Files Appeal in CRG Case

Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.081 loss in 3Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics Inc. Announces Court Made an Oral Ruling from Bench in Open Court At the Conclusion of the Trial in Case No. 2018-24442-151

Navidea Biopharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $14.2 million.

Second quarter 2022 earnings released: US$0.099 loss per share (vs US$0.092 loss in 2Q 2021)

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

First quarter 2022 earnings released: US$0.099 loss per share (vs US$0.11 loss in 1Q 2021)

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc. Announces Positive Preliminary Results of its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India

Navidea Biopharmaceuticals Receives Acceptance Letter from Nyse American

Navidea Biopharmaceuticals Announces Executive Changes

Navidea Biopharmaceuticals Announces Receipt of Noncompliance Notice from NYSE American

Forecast to breakeven in 2024

Navidea Biopharmaceuticals, Inc. Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Programram

Navidea Biopharmaceuticals, Inc. Provides Update on Litigation with Capital Royalty Partners II L.P

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.13 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

Independent Director Claudine Bruck has left the company

Independent Chairman of the Board Sarah Rouan has left the company

Consensus revenue estimates increase to US$9.39m

Second quarter 2021 earnings released: US$0.092 loss per share (vs US$0.11 loss in 2Q 2020)

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

John K. Scott Requests Navidea Biopharmaceuticals to Appoint Two Additional Members to the Board

Consensus forecasts updated

Chief Business Officer has left the company

Full year 2020 earnings released: US$0.48 loss per share (vs US$0.76 loss in FY 2019)

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Navidea Biopharmaceuticals, Inc. Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

New 90-day high: US$2.89

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

New 90-day low: US$2.16

Revenue and earnings beat expectations

Third quarter 2020 earnings released: US$0.13 loss per share

Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients from Its Ongoing Phase 2B Study in Rheumatoid Arthritis

New 90-day low: US$2.21

New 90-day low: US$2.58

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation At the American College of Rheumatology Annual Meeting

New 90-day low: US$2.64

Analysts lower revenue estimates to US$763.5k

First half earnings released